首页> 外文期刊>Cancer control : >Quantitative HBV DNA and AST are strong predictors for survival after HCC detection inchronic HBV patients
【24h】

Quantitative HBV DNA and AST are strong predictors for survival after HCC detection inchronic HBV patients

机译:HBV DNA和AST是HCC检测到慢性HBV患者后生存的有力预测指标

获取原文
           

摘要

Hepatitis B virus infection (HBV) is an important co-factor in the development of hepatocellular carcinoma (HCC). We studied whether quantitative HBV DNA at time of HCC detection influences survival of HCC patients. All diagnosed HCC cases between 2000 and 2008 at our university-based reference centre were analysed to determine the influence of hepatitis B viral load on overall survival. Clinical and virological findings were evaluated in univariate and multivariate analyses, survival rates were assessed for HCC patients with a high viral load (HBV DNA ≥105 copies/ml) and low viral load (HBV DNA <105 copies/ml). HCC was diagnosed in 597 patients, including 98 patients with HBV. The group of 37 patients (38%) who had a high viral load contained more HBeAg-positive patients, had lower serum albumin levels and higher serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. The one- and five-year survival rates of HCC patients with a high viral load were 58% and 11% and for HCC patients with a low viral load 70% and 35%, respectively. In multivariate analysis a higher AST level and higher viral load were significantly associated with shorter overall survival (HR=2.30; p=0.018, HR=1.22; p=0.015, respectively). HBeAg positivity, low albumin level or high AST or ALT levels in HCC patients are associated with a higher HBV DNA . HBV DNA level at detection is associated with overall survival of HCC patients. These findings support the concept that after HCC detection adequate suppression of HBV DNA by nucleoside analogue therapy may improve survival.
机译:乙型肝炎病毒感染(HBV)是肝细胞癌(HCC)发生的重要辅助因素。我们研究了检测HCC时定量HBV DNA是否会影响HCC患者的生存。在我们位于大学的参考中心内,对2000年至2008年之间所有诊断出的HCC病例进行了分析,以确定乙型肝炎病毒载量对总体生存的影响。通过单因素和多因素分析评估临床和病毒学发现,评估高病毒载量(HBV DNA≥105拷贝/ ml)和低病毒载量(HBV DNA <105拷贝/ ml)的HCC患者的生存率。 597例患者被诊断出HCC,其中包括98例HBV患者。病毒载量较高的37例患者(38%)中,HBeAg阳性患者较多,血清白蛋白水平较低,血清天冬氨酸转氨酶(AST)和丙氨酸转氨酶(ALT)较高。高病毒载量的HCC患者的一年和五年生存率分别为58%和11%,低病毒载量的HCC患者分别为70%和35%。在多变量分析中,较高的AST水平和较高的病毒载量与较短的总生存期显着相关(分别为HR = 2.30; p = 0.018; HR = 1.22; p = 0.015)。 HCC患者中的HBeAg阳性,白蛋白水平低或AST或ALT高与HBV DNA升高有关。检测时的HBV DNA水平与HCC患者的整体生存率有关。这些发现支持了这样的概念,即在检测出HCC之后,通过核苷类似物疗法对HBV DNA的充分抑制可以提高生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号